Followers | 3183 |
Posts | 208744 |
Boards Moderated | 2 |
Alias Born | 02/04/2004 |
Friday, August 06, 2021 11:04:10 AM
Plus, logic also strongly suggests that with "so many" already biotech sector big board executives serving right TSOI's advisory board & executive mgmt rosters, that "all" of them have been speaking to BIG pharma companies they already serve on Boards of, and/or already know which big pharma company would make the optimal JadiCell collaborative partner instead of TSOI being foolish enough to go it alone.
In fact, today's CEO Dixon post about applying for EUA is yet another strong tell that a pending big pharma collaborative partner announcement is most likely pending, as why wouldn't TSOI partner with a big pharma firm to save lives and cure the scar tissue on the lungs many covid long haulers are already currently suffering from, with a multitude more covid infected people around the world to soon be suffering from scar tissue damaged lungs to come right!
And for anyone claiming TSOI's a dilution play it bears noting that TSOI is a full SEC Reporting PubCo that files fully audited financials and has a green shield verified DTC deposited tradable float verified on OTC Markets each month by the transfer agent directly to OTC Markets.
And absolutely "none" of the distinguished biotech sector executives surrounding CEO Dixon would ever let him claim no dilution required to pay for JadiCell Phase III if it wasn't true...because all of them are only heavily involved with TSOI because they "all" are already convinced their direct involvement with TSOI is going to "enhance" their already distinguished biotech sector careers right!
Dr. Ichim alone serves as BOD or Advisory Board member on 7 big board biotech PubCo's if memory serves for an example of the sheer quality of established bio sector executives right alongside CEO Dixon at this precise juncture, and 1 can only imagine who they've already identified as the best/most optimal collaborative partner to aid and assist them in getting their novel JadiCell IP solution to the world ASAP.
Here's the latest updated DTC deposited float as of this week by the way:
Held at DTC
1,129,681,369
08/03/2021
And here's what it was back in May which was 3 months ago cheers:
Held at DTC
1,075,956,980
05/19/2021
Recent TSOI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:29:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM